The publication aims to assess whether SGLT2 inhibitors, compared to DPP-4 inhibitors, are associated with an increased risk for diabetic ketoacidosis in people with type 2 diabetes.
Citation
Anat Fisher MD, Michael Fralick MD, Kristian B. Filion PhD, Sophie Dell’Aniello MSc, Antonios Douros MD, Éric Tremblay BPharm, Baiju R. Shah MD, Paul E. Ronksley PhD, Silvia Alessi-Severini PhD, Nianping Hu PhD, Shawn C. Bugden PharmD, Pierre Ernst MD, Lisa M. Lix PhD, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, https://doi.org/10.1111/dom.14082